Newborn Screening for Biotinidase Deficiency. The Experience of a Regional Center in Italy

Introduction: Biotinidase deficiency (BD) is an autosomal recessive disease causing a defect in the biotin-releasing enzyme. Newborn screening (NBS) allows early diagnosis and treatment, ensuring excellent prognosis. The aim of this study was to describe our experience in the diagnosis, treatment, and follow-up showing key strategies and unsolved questions of the management of BD patients. Methods: We analyzed data of patients identified by the Regional Centre for Newborn Screening of Verona and followed by the Inherited Metabolic Disease Unit of Verona and Neonatal Intensive Care Unit of Bolzano, Italy, from 2014 to 2020. Results: Thirty-seven patients were diagnosed by NBS (five profound and 32 partial BD), with a total incidence of 1:5,996. All were started on biotin at diagnosis and presented no symptoms at follow-up. Analysis of parents and siblings led to identification of five asymptomatic patients with partial BD: one asymptomatic parent and four young siblings. Genetic analysis of the BTD gene identified 17 different genotypes and one mutation not previously known. Discussion: Our data confirm that NBS introduction had a dramatic impact on BD diagnosis, and the incidence has increased significantly compared to other areas. Partial defects are more common than profound and have a distinctive genotype. Partial BD treatment is still controversial even at what dose of biotin and for how long. At the end, BD treatment is very easy and inexpensive and prevents severe neurological damage. Sharing experiences is essential to achieving guidelines for treatment and follow-up and a better genotype–phenotype correlation.

[1]  G. la Marca,et al.  High frequency of biotinidase deficiency in Italian population identified by newborn screening , 2020, Molecular genetics and metabolism reports.

[2]  F. Ozkinay,et al.  Single center experience of biotinidase deficiency: 259 patients and six novel mutations , 2018, Journal of pediatric endocrinology & metabolism : JPEM.

[3]  N. Mungan,et al.  Twenty-seven mutations with three novel pathologenic variants causing biotinidase deficiency: a report of 203 patients from the southeastern part of Turkey , 2018, Journal of pediatric endocrinology & metabolism : JPEM.

[4]  T. Cowan,et al.  Laboratory diagnosis of biotinidase deficiency, 2017 update: a technical standard and guideline of the American College of Medical Genetics and Genomics , 2017, Genetics in Medicine.

[5]  M. R. Carvalho,et al.  Correction: Biotinidase deficiency: Genotype-biochemical phenotype association in Brazilian patients , 2017, PloS one.

[6]  T. Félix,et al.  Biotinidase deficiency: Genotype-biochemical phenotype association in Brazilian patients , 2017, PloS one.

[7]  B. Wolf.  Successful outcomes of older adolescents and adults with profound biotinidase deficiency identified by newborn screening , 2016, Genetics in Medicine.

[8]  Maria D. Karaceper,et al.  Biotinidase deficiency: Spectrum of molecular, enzymatic and clinical information from newborn screening Ontario, Canada (2007-2014). , 2015, Molecular genetics and metabolism.

[9]  B. Wolf.  Why screen newborns for profound and partial biotinidase deficiency? , 2015, Molecular genetics and metabolism.

[10]  G. Feldman,et al.  Outcomes of individuals with profound and partial biotinidase deficiency ascertained by newborn screening in Michigan over 25 years , 2014, Genetics in Medicine.

[11]  Y. L. Loukas,et al.  High incidence of partial biotinidase deficiency cases in newborns of Greek origin. , 2013, Gene.

[12]  B. Wolf.  Biotinidase deficiency: “if you have to have an inherited metabolic disease, this is the one to have” , 2012, Genetics in Medicine.

[13]  B. Wolf.  Clinical issues and frequent questions about biotinidase deficiency. , 2010, Molecular genetics and metabolism.

[14]  D. Babovic‐Vuksanovic,et al.  High incidence of profound biotinidase deficiency detected in newborn screening blood spots in the Somalian population in Minnesota , 2009, Journal of Inherited Metabolic Disease.

[15]  N. Blau,et al.  Laboratory guide to the methods in biochemical genetics , 2008 .

[16]  Á. Schuler,et al.  Mutations causing biotinidase deficiency in children ascertained by newborn screening in Western Hungary. , 2007, Molecular genetics and metabolism.

[17]  B. Wolf,et al.  Asymptomatic adults and older siblings with biotinidase deficiency ascertained by family studies of index cases , 2005, Journal of Inherited Metabolic Disease.

[18]  D. Goudie,et al.  Biotinidase deficiency: Novel mutations and their biochemical and clinical correlates , 2005, Human mutation.

[19]  B. Wolf.  Worldwide survey of neonatal screening for biotinidase deficiency , 1991, Journal of Inherited Metabolic Disease.

[20]  B. Wolf,et al.  Neonatal screening for biotinidase deficiency in Hungary: Clinical, biochemical and molecular studies , 2003, Journal of Inherited Metabolic Disease.

[21]  T. Suormala,et al.  Seventeen novel mutations that cause profound biotinidase deficiency. , 2002, Molecular genetics and metabolism.

[22]  C. Item,et al.  Molecular characterisation of 34 patients with biotinidase deficiency ascertained by newborn screening and family investigation , 2001, European Journal of Human Genetics.

[23]  B. Wolf,et al.  Mutations Causing Profound Biotinidase Deficiency in Children Ascertained by Newborn Screening in the United States Occur at Different Frequencies than in Symptomatic Children , 1999, Pediatric Research.

[24]  E. Mayatepek,et al.  Partial biotinidase deficiency is usually due to the D444H mutation in the biotinidase gene , 1998, Human Genetics.

[25]  G. Buck,et al.  Mutations in the Human Biotinidase Gene That Cause Profound Biotinidase Deficiency in Symptomatic Children: Molecular, Biochemical, and Clinical Analysis , 1997, Pediatric Research.

[26]  G. Buck,et al.  Mutation (Q456H) is the most common cause of profound biotinidase deficiency in children ascertained by newborn screening in the United States. , 1997, Biochemical and molecular medicine.